Pluvicto? (lutetium LU 177 vipivotide tetraxetan)

Ended Awarded Last action

Contract number
36C26125F0023
Awardee
Awarding agency
Obligated
$1,063,332

Award facts

Contract value 100% obligated
$1,063,332.48 Current and potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
Pricing
Firm Fixed Price
Place of performance
East Hanover, NJ 07936, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00002 -$2,924,164
Supplemental Agreement for work within scope P00001 $14,406
Original award $3,973,091

About this award

Veterans Integrated Service Network 21 issued a delivery order to Advanced Accelerator Applications USA Inc. on October 1, 2024, for PLUVICTO (lutetium Lu 177 vipivotide tetraxetan), a targeted radioligand therapy for prostate cancer treatment, with a ceiling value of $1,063,332.48 under the GSA Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB).

The order calls for firm fixed-price supply of the FDA-approved radiopharmaceutical with place of performance in East Hanover, NJ. Ultimate completion is September 30, 2025. No set-aside was used. Advanced Accelerator Applications USA Inc., a Novartis subsidiary, is the primary federal supplier of specialized radiopharmaceuticals to the Veterans Health Administration and Defense Health Agency, with an established portfolio of lutetium Lu 177–based therapies delivered through GSA schedule and blanket purchase agreement vehicles.

Quick answers

Who was awarded contract 36C26125F0023?

36C26125F0023 was awarded to Advanced Accelerator Applications USA Inc. by Veterans Integrated Service Network 21 (Veterans Health Administration) on October 1, 2024.

How much is contract 36C26125F0023 worth?

The government has obligated $1,063,332 on 36C26125F0023.

Is contract 36C26125F0023 an order under another contract?

Yes. 36C26125F0023 is a delivery order under 36F79719D0169, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).

Was contract 36C26125F0023 competed?

The extent of competition for 36C26125F0023 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award